AiCuris Anti-infective Cures GmbH

AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially lifethreatening infectious diseases.
Since November 2017, the first product from AiCuris is on the market. Letermovir, designed to inhibit the viral terminase of the human cytomegalovirus (CMV) and licensed to MSD, achieved market approval in the US, Europe and Japan for the prophylaxis of CMV infections in recipients of bone marrow transplants.

Further clinical programs include Pritelivir, a helicase-primase inhibitor, developed to treat recurrent labial herpes and genital herpes infections, AIC499, a resistancebreaking Gram(-) antibiotic and AIC649, an immune modulator targeted at Hepatitis B cure.

Overview:

Field of Activity	Anti-infectives including antivirals (HCMV, HSV, Hepatitis B virus, Adenovirus) and antibacterials (hospital infections caused by multiresistant Gram-negative and Gram-positive bacteria).
Ownership Structure and Financing	Private investors, led by the family offi ce of the Dres. Strüngmann, former owners of Hexal.
Partners	Merck & Co. (MSD): Licensee of AiCuris’ HCMV drug Letermovir. AiCuris intends to move its projects to a clinical proof-of-concept and then to offer them for licensing/partnering. AiCuris is open for various types of collaborations and also pursues an active in-licensing strategy for early pre-clinical projects.
Products / Services	AiCuris’ Clinical Programs: Letermovir, HCMV, Registration (licensed to Merck&Co, MSD) AIC387 / AIC476, HCMV, Phase 1 Pritelivir, oral, HSV (genital herpes), Phase 2 Pritelivir, topical, HSV (labial herpes), Phase 2 AIC649, Hepatitis B Virus, Phase 1 AIC499, Gram-hospital infections, Phase 1
Unique Selling Point	AiCuris’ innovative antibiotic and antiviral drugs act via new modes of action and are directed against new targets and/or represent novel chemical classes. Based on this, AiCuris‘ therapeutics are resistance-breaking by design.
Membership in networks / associations	BIO Deutschland, BioRiver, European Biopharmaceutical Enterprises (EBE), BEAM-Alliance
Date of Incorporation	2006
Number of Employees	65